News / Taiwan / economic_daily
PharmaEssentia Partners with Novotech to Accelerate Australian Market Expansion
Health Technology · Biotechnology · economic_daily · 2026-10-22
6446
PharmaEssentia CEO Lin Kuo-chung signed an MOU with Novotech during the 2026 AusBiotech conference to advance the clinical development and commercialization of its drug Ropeg in Australia.
What Happened
Strategic Partnership: PharmaEssentia CEO Lin Kuo-chung led a delegation to the 2026 AusBiotech conference, where the company signed a Memorandum of Understanding (MOU) with Novotech, a leading Australian clinical research organization. This collaboration aims to deepen research ties and serves as a pivotal step in the company's broader strategy to expand its footprint across the Asia-Pacific region.
Regulatory Progress: The company is actively preparing for the regulatory submission of its drug, Ropeg, for both polycythemia vera (PV) and essential thrombocythemia (ET) in Australia. By engaging with local healthcare systems and key opinion leaders, PharmaEssentia aims to accelerate the approval process and provide new therapeutic options to Australian patients.
Operational Expansion: Following the establishment of its Melbourne subsidiary in October, PharmaEssentia is aggressively building its local operational team and recruiting senior talent with commercialization expertise. CEO Lin emphasized that the company is translating its market entry strategy into concrete actions to ensure a robust presence in the Australian pharmaceutical landscape.
Industry Engagement: The 2026 AusBiotech conference, which attracted approximately 2,000 global participants, provided a platform for PharmaEssentia to network with industry experts and potential partners. This participation not only enhances the company's international profile but also facilitates the integration of resources necessary for its long-term commercial success in the region.